<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384744</url>
  </required_header>
  <id_info>
    <org_study_id>2019001</org_study_id>
    <nct_id>NCT04384744</nct_id>
  </id_info>
  <brief_title>To Explore the Effect of GH on Outcomes of IVF and Telomerase Activity of Granulosa Cells in Women With POR</brief_title>
  <official_title>To Explore the Effect of Growth Hormone on Outcomes of in Vitro Fertilisation and Telomerase Activity of Granulosa Cells in Women With Poor Ovarian Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou First People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is still a big difficult clinical problem for patients with poor ovarian reserve
      undergoing in vitro fertilization. The decrease in both quality and quantity of egg are the
      main cause for poor clinical prognosis. Growth hormone (GH) is currently one of the main
      adjuvant for improving pregnancy outcomes in patients with POR, and the investigators'
      previous retrospective study suggested GH was effective in live birth rate in subgroup of
      patients with POR older than 35 years old. To further figure out the mechanism of GH
      effectiveness in POR patients and the effect on clinical outcomes in POR patients, the
      investigators designed this prospective observational cohort study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 26, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>1-2 years</time_frame>
    <description>Clinical pregnancy means pregnancy sac is seen intrauterine under ultrasound 7 weeks after embryo transferred.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>live birth rate</measure>
    <time_frame>1-2 years</time_frame>
    <description>Live birth rate(%): number of live birth/ transferred cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of oocytes retrieved</measure>
    <time_frame>1-2 years</time_frame>
    <description>number of oocytes retrieved on day of OPU</description>
  </secondary_outcome>
  <other_outcome>
    <measure>telomerase activity of granulosa cells</measure>
    <time_frame>1-2 years</time_frame>
    <description>detection of telomerase activity of granulosa cells in wasted follicular fluid</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>GH</condition>
  <condition>Poor Ovarian Reserve Based on POSEIDON</condition>
  <arm_group>
    <arm_group_label>GH-POR</arm_group_label>
    <description>Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGH-POR</arm_group_label>
    <description>Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGH-NOR</arm_group_label>
    <description>Participants with normal ovarian reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>growth hormone</intervention_name>
    <description>growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.</description>
    <arm_group_label>GH-POR</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      follicular fluid abandoned
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients diagnosed as POR based on POSEIDON criteria and with
        low ovairan reserve, as well as patients with normal ovairan reserve seeking for ART help
        due to pelvic tubal factors.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For patients with poor ovarian response, the criteria is based on POSEIDON criteria[1]:

          1. low ovarian reserve(AMH &lt;1.2ng/ml, or AFC &lt;5);

          2. younger than 40.

        For patients with normal ovarian reserve, the criteria is as follow:

          1. Patients who are between 20-40 years old;

          2. clinical diagnosis of non-functional fallopian tube;

          3. regular menstrual cycles.

        Exclusion Criteria:

          1. BMI ≥28kg/m2;

          2. medical diseases such as endocrine and metabolic diseases, autoimmune disease, etc;

          3. ovarian neoplasm that ≥4 cm in diameter and has no clear pathological diagnosis by
             surgery;

          4. adenomyosis or endometriosis confirmed by surgery;

          5. untreated abnormal intrauterine environment, such as uterine effusion, endometritis,
             etc;

          6. untreated hydrosalpinx;

          7. polycystic ovary syndrome.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>meihong Cai, master</last_name>
    <role>Study Director</role>
    <affiliation>Guangzhou First People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>meihong Cai, master</last_name>
    <phone>15889936054</phone>
    <email>caimhong@mail2.sysu.edu.cn</email>
  </overall_contact>
  <results_reference>
    <citation>Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number), Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, Ubaldi FM, Humaidan P. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016 Jun;105(6):1452-3. doi: 10.1016/j.fertnstert.2016.02.005. Epub 2016 Feb 26.</citation>
    <PMID>26921622</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>growth hormone</keyword>
  <keyword>POSEIDON</keyword>
  <keyword>low ovarian reserve</keyword>
  <keyword>prospective observational cohort study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

